CBD

Hook

CBD is one of the clearest cases where the page should resist canonization until the burden of specificity is met. Hemp-derived cannabidiol products vary too widely in dose, route, spectrum, legality, and interaction profile to be written as if they were one herb on one shelf. Public interest is real. So are the uncertainties. A responsible page keeps that complexity visible from the first line, which is exactly why CBD remains a hold in this lane. It can be described, but not casually absorbed into the same confidence register as chamomile or hawthorn.

What it is for

Cannabidiol (CBD) represents one of the most pharmacologically complex plant compounds studied, with a multi-receptor binding profile unlike any other botanical. Present at 1-25% dry weight depending on cultivar, CBD is supported by cannabidiolic acid (CBDA, dominant in raw plant), cannabigerol (CBG, 0.1-2%), the sesquiterpene beta-caryophyllene (which is itself a CB2 agonist), monoterpenes including myrcene, limonene, and linalool, and the unique prenylated flavonoids cannflavins A and B. Three preparation categories exist: full-spectrum (CBD + minor cannabinoids + terpenes + <0.3% THC), broad-spectrum (THC removed), and isolate (>99% pure CBD). CBD's receptor pharmacology is extraordinary in its breadth: it acts as an agonist at TRPV1, TRPV2, and TRPA1 (activating then desensitizing pain receptors), agonist at PPARgamma (mediating anti-inflammatory and neuroprotective effects), positive allosteric modulator at 5-HT1A (enhancing serotonergic signaling for anxiolysis), negative allosteric modulator at CB1/CB2 (reducing CB1 efficacy without direct antagonism), antagonist at GPR55 (relevant to bone density and cancer cell proliferation), adenosine reuptake inhibitor via ENT1 blockade (increasing extracellular adenosine for anti-inflammatory effect), and weak FAAH inhibitor (modestly increasing endocannabinoid tone). FDA-approved as Epidiolex for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, with Phase 3 RCTs demonstrating 38.9% reduction in monthly convulsive seizures versus 13.3% placebo. Anxiolytic effects are supported at doses of 300mg or greater.

CBD is usually reached for when the conversation involves anxiety, pain, sleep, or inflammation, but it belongs first to the formulation-and-interaction lane rather than to simple herb storytelling.